Document Detail

Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer.
MedLine Citation:
PMID:  11885999     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Because of the increasing number of long-term survivors of metastatic testicular germ-cell cancer, a general concern has been secondary morbidities, especially cardiovascular risk factors. PATIENTS AND METHODS: Thirty-two patients treated with cisplatin- and doxorubicin-containing chemotherapy > or = 13 years before the time of analyses were evaluated for neuro-, oto-, pulmonary-, vascular- and gonadal toxicity including evaluation of myocardial damage and cardiovascular risk factors and analysis of microcirculation. RESULTS: Thirty percent of the patients showed abnormal left ventricle function. Elevated follicle stimulating hormone (FSH) and luteinising hormone (LH) levels in 75% of patients were often associated with low testosterone levels. Elevated total cholesterol levels were found in 82% and higher triglyceride levels in 44% of patients, most of them were overweight. About 25% of the patients developed diastolic arterial hypertension after chemotherapy. Reduced hearing was confirmed in 23% of patients, especially at frequencies higher than 3000 Hz. Moreover, 53% of patients presented transient evoked otoacoustic emissions. In 38% of patients non-symptomatic neuropathy was detected, in 28% symptomatic neuropathy, and in 6% disabling polyneuropathy. In 80% of patients with neuropathic symptoms additional morphological and functional abnormalities were found by nailfold capillary videomicroscopy, compared to only 57% of the patients without neuropathic symptoms. CONCLUSIONS: Patients cured by cisplatin-based chemotherapy for metastatic testicular cancer have to be cognizant of their unfavorable cardiovascular risk profile, that might be a greater risk than developing a relapse or second malignancy.
D Strumberg; S Brügge; M W Korn; S Koeppen; J Ranft; G Scheiber; C Reiners; C Möckel; S Seeber; M E Scheulen
Related Documents :
12713079 - C-reactive protein and anti-chlamydia pneumoniae antibodies as risk factors of cardiova...
19013649 - The acquisition and outcome of icu-acquired clostridium difficile infection in a single...
17920359 - Effect of intracoronary thrombectomy on 30-day mortality in patients with acute myocard...
19298569 - Heart rate turbulence as a predictor of cardiac mortality and arrhythmic events in pati...
18556379 - Impact of early nephrology referral on mortality and hospitalization in peritoneal dial...
15485419 - Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hype...
24166719 - Psoriasis, electrocardiographic characteristics, and incidence of atrial fibrillation.
2315229 - Neuropeptide y as a marker in pediatric neuroblastoma.
16846439 - Significance of qrs duration changes in the evaluation of st-segment depression present...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  13     ISSN:  0923-7534     ISO Abbreviation:  Ann. Oncol.     Publication Date:  2002 Feb 
Date Detail:
Created Date:  2002-03-11     Completed Date:  2002-08-22     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  229-36     Citation Subset:  IM    
Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Essen.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Blood Pressure / drug effects
Cisplatin / adverse effects*
Fertility / drug effects
Follicle Stimulating Hormone / blood
Hearing / drug effects
Heart / drug effects
Luteinizing Hormone / blood
Middle Aged
Peripheral Nervous System Diseases / chemically induced
Testicular Neoplasms / drug therapy*
Reg. No./Substance:
15663-27-1/Cisplatin; 9002-67-9/Luteinizing Hormone; 9002-68-0/Follicle Stimulating Hormone
Comment In:
Ann Oncol. 2002 Feb;13(2):187-9   [PMID:  11885993 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Long-term renal function after treatment for malignant germ-cell tumours.
Next Document:  Routine computerised tomographic scans of the thorax in surveillance of stage I testicular non-semin...